

1000 JOURNAL OF CLIMATE

"


[illegible]

9

66



GFH3754W8{"ÚEuKRAS G12D#''#´ ¨8r ¬,p&öGö\$ÇTá¹QÆ%zG >G6â4à



GFH375 in combination with

Efficacy in Pretreated KRAS G12D -mutant mCRC

- Median follow -up: 5.7 months (range: 2.8, 9.2).
- 65% (35/54) of patients remain on treatment.
- ORR: 44% (24/54), 11 uPR (8 patient40.8 0ai

GFH375 600 mg QD + cetuximab 500 mg/m ² Q2W (N=54)	
ORR: % (95%CI)	44 (31, 59)
DCR: % (95%CI)	89 (77, 96)

Data cutoff: 16 -Sep-2026. All patients received a first dose of GFH375 in combination with cetuximab at least 12 weeks prior to data cutoff date. Two patients with CRC who lack post -baseline tumor assessments are not displayed in the waterfall but included in the denominator for ORR. Three patients with uPR discontinued treatment: 1 due to PD, 1 per patient decision, and 1 to initiate a new anticancer therapy.
CI, confidence interval; cPR, confirmed partial response; CRC, colorectal cancer; DCR, disease control rate; ORR, overall response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; QD, once daily; Q2W, Quaque 2 weeks; SD, stable disease; uPR, unconfirmed partial response.

PFSin Pretreated KRAS G12D -mutant CRC

- PFS events: n=16, 35 remain on treatment.
- Median PFS was 7.3 months with median follow-up time of 5.4 months.
- 4-months PFS rate, % (95%CI): 78 (62 88).

Number at risk

54 51 44 40 24 23 3 3 2 0

Data cutoff: 16 - Sep-2026. All patients received a first dose of GFH375 in combination with cetuximab at least 12 weeks prior to data cutoff date. Four patients dropped out early, including 3 per patient decision and 1 per investigator decision.

CI, confidence interval; CRC, colorectal cancer; PD, progressive disease; PFS, progression-free survival.

(o"÷Dù"°U)1 %U8•KRAS G12D #' #'>-G {*™RAS Kó%JG–K?BTD

KRAS G12D



GFH276>-G - ÅG—#•<×6â4à-x(šESMO LBA4 %¼ ÿ%C/u

GFH375/VS-7375 iö] </æ0 aM"x rP1QÆ%zG >GPDAC"p1™III8'I†Kè

